OneSpan Inc vs Zoetis Inc — how do they compare? OneSpan Inc trades at $15.2 (market cap $571.66M), while Zoetis Inc trades at $74.43 (market cap $31.59B). The key difference: Zoetis Inc is far larger — about 55.3× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (3.37%). Which is the better fit depends on your goals.
| OSPN | ZTS | |
|---|---|---|
Market Cap | $571.66M | $31.59B |
Sector | Technology | Health |
52-Week High | $16.32 | $156.76 |
52-Week Low | $10.15 | $71.91 |
Enterprise Value | $529.87M | $38.89B |
Dividend Yield | 3.37% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $15.51, up 0.26% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 28.47% net income margin and a low P/E of 8.57, indicating potential undervaluation. Recent earnings have consistently beaten expectations, and the company announced a $0.13 dividend for H1 2026. Analyst sentiment is positive with a 66.7% buy rating, though the consensus price target of $13.50 is below the current price.
The outlook for OSPN is cautiously optimistic, supported by solid fundamentals and positive earnings momentum. Key opportunities include attractive valuation and consistent profitability. Risks include negative net cash flow trends and competitive pressures in the cybersecurity sector. Investors should weigh the strong analyst buy sentiment against the below-consensus price target.
No Aura AI signal available yet.
Trailing returns across standard periods
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →